ObsEva SA (OBSV) Given “Buy” Rating at Royal Bank Of Canada
ObsEva SA (NASDAQ:OBSV)‘s stock had its “buy” rating reissued by investment analysts at Royal Bank Of Canada in a research report issued on Thursday. They presently have a $22.00 price objective on the stock. Royal Bank Of Canada’s price objective would indicate a potential upside of 105.42% from the stock’s current price.
Other research analysts have also recently issued reports about the stock. HC Wainwright reissued a “buy” rating and set a $27.00 price target on shares of ObsEva SA in a research report on Wednesday, October 4th. Zacks Investment Research raised shares of ObsEva SA from a “sell” rating to a “buy” rating and set a $11.00 price target for the company in a research report on Wednesday, October 18th. Leerink Swann reissued an “outperform” rating and set a $18.00 price target on shares of ObsEva SA in a research report on Wednesday, August 16th. Finally, Credit Suisse Group started coverage on shares of ObsEva SA in a research note on Monday, October 9th. They set an “outperform” rating and a $16.00 price objective for the company. Six analysts have rated the stock with a buy rating, ObsEva SA has an average rating of “Buy” and a consensus price target of $18.83.
ObsEva SA (NASDAQ:OBSV) last issued its quarterly earnings results on Tuesday, August 15th. The company reported ($0.61) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.13). During the same quarter in the prior year, the firm earned ($0.30) EPS.
COPYRIGHT VIOLATION NOTICE: This news story was posted by American Banking News and is owned by of American Banking News. If you are reading this news story on another domain, it was illegally copied and reposted in violation of US & international trademark and copyright law. The legal version of this news story can be accessed at https://www.americanbankingnews.com/2017/11/02/obseva-sa-obsv-given-buy-rating-at-royal-bank-of-canada.html.
A number of large investors have recently added to or reduced their stakes in the business. Sectoral Asset Management Inc increased its stake in ObsEva SA by 181.9% during the 2nd quarter. Sectoral Asset Management Inc now owns 212,831 shares of the company’s stock valued at $1,820,000 after purchasing an additional 137,331 shares in the last quarter. VHCP Management II LLC bought a new stake in ObsEva SA during the 2nd quarter valued at about $1,283,000. Sphera Funds Management LTD. increased its stake in ObsEva SA by 9.7% during the 2nd quarter. Sphera Funds Management LTD. now owns 231,497 shares of the company’s stock valued at $1,979,000 after purchasing an additional 20,411 shares in the last quarter. Finally, Paloma Partners Management Co bought a new stake in ObsEva SA during the 1st quarter valued at about $131,000. Institutional investors and hedge funds own 48.46% of the company’s stock.
About ObsEva SA
Obseva SA is a Switzerland-based company active in the pharmaceutical and medical research sector. The Company develops oral compounds to treat women’s reproductive health conditions from conception to birth. Its pipeline includes three product candidates: OBE2109 is an oral gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and blocks the endogenous GnRH from activating its pituitary receptors, which reduces estrogen production by the ovaries and leads to amenorrhea.
Receive News & Ratings for ObsEva SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ObsEva SA and related companies with MarketBeat.com's FREE daily email newsletter.